Current management of barrett esophagus and esophageal adenocarcinoma

Abstract

Barrett esophagus is found in 5% to 15% of patients with gastroesophageal refl ux disease and is a precursor of esophageal adenocarcinoma, yet the condition often goes undiagnosed. Patients with refl ux disease who are male, over age 50, or white, and who smoke or have central obesity or a family history of Barrett esophagus or esophageal adenocarcinoma, should undergo initial screening endoscopy and, if no dysplasia is noted, surveillance endoscopy every 3 to 5 years. Dysplasia is treated with endoscopic eradication by ablation, resection, or both. Chemoprotective agents are being studied to prevent progression to dysplasia in Barrett esophagus. The authors discuss current recommendations for screening and management.